Skip to content

Study · Observational study · 2025

7 results

Improvement in Helicobacter pylori Eradication Among Adults Receiving Semaglutide: A Population-Based Propensity-Score-Adjusted Analysis.

Ness A, Levi Z, Belfer RG, Dickman R, Boltin D

Helicobacter1 Jan 2025Cited by 1 (Europe PMC)

PMID39902748 (opens in a new tab)PMCIDPMC11792433 (opens in a new tab)DOI10.1111/hel.70014 (opens in a new tab)PepBankPUB-39902748
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In treated adults with H. pylori, semaglutide exposure was linked to higher eradication than no GLP-1 drug exposure.

    In plain wordsIn adults treated for H. pylori, semaglutide was linked to higher eradication than no GLP-1 drug exposure.

    Peptide
    Semaglutide
    Outcome
    IncreaseH. pylori eradication
    Study

    n: not reported in source

    Comparator
    No GLP-1 drug exposure
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Measurements

    Eradication rate
    93.8%
    Adults treated for H. pylori who received semaglutide
    Odds ratio for eradication
    2.78 ratio
    Semaglutide recipients
    95% CI of odds ratio for eradication
    1.32 to 5.83 ratio
    Semaglutide recipients

    Source sentences

    Summary
    Eradication among those who received semaglutide was 93.8% (OR 2.78, 95% CI 1.32-5.83, p = 0.007).
    2 context sentences
    Summary · context
    Adults with a new diagnosis of H. pylori infection who received treatment between 2014 and 2023 were identified in the Clalit Health Services database.
    Summary · context
    A 1:2 propensity-score matched dataset was used to determine the effect of GLP-1 drugs on eradication success.
  2. 02HumanObservational studyEfficacy outcome

    In treated adults with H. pylori, dulaglutide showed no significant eradication difference versus no GLP-1 drug exposure.

    In plain wordsIn adults treated for H. pylori, eradication did not differ significantly with dulaglutide versus no GLP-1 drug exposure.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeH. pylori eradication
    Study

    n: not reported in source

    Comparator
    No GLP-1 drug exposure
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Measurements

    Eradication rate
    88.6%
    Adults treated for H. pylori who received dulaglutide

    Source sentences

    Summary
    Eradication in subjects who received dulaglutide (88.6%) or liraglutide (81.4%) was not significantly changed.
    2 context sentences
    Summary · context
    Adults with a new diagnosis of H. pylori infection who received treatment between 2014 and 2023 were identified in the Clalit Health Services database.
    Summary · context
    A 1:2 propensity-score matched dataset was used to determine the effect of GLP-1 drugs on eradication success.
  3. 03HumanObservational studyEfficacy outcome

    In treated adults with H. pylori, liraglutide showed no significant eradication difference versus no GLP-1 drug exposure.

    In plain wordsIn adults treated for H. pylori, eradication did not differ significantly with liraglutide versus no GLP-1 drug exposure.

    Peptide
    Liraglutide
    Outcome
    No significant changeH. pylori eradication
    Study

    n: not reported in source

    Comparator
    No GLP-1 drug exposure
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Measurements

    Eradication rate
    81.4%
    Adults treated for H. pylori who received liraglutide

    Source sentences

    Summary
    Eradication in subjects who received dulaglutide (88.6%) or liraglutide (81.4%) was not significantly changed.
    2 context sentences
    Summary · context
    Adults with a new diagnosis of H. pylori infection who received treatment between 2014 and 2023 were identified in the Clalit Health Services database.
    Summary · context
    A 1:2 propensity-score matched dataset was used to determine the effect of GLP-1 drugs on eradication success.
  4. 04HumanObservational studyEfficacy outcome

    In treated adults with H. pylori, propensity-adjusted eradication remained higher with semaglutide than no GLP-1 drug exposure.

    In plain wordsIn adults treated for H. pylori, adjusted eradication remained higher with semaglutide than no GLP-1 drug exposure.

    Peptide
    Semaglutide
    Outcome
    IncreasePropensity-adjusted H. pylori eradication
    Study

    n: not reported in source

    Comparator
    No GLP-1 drug exposure
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Measurements

    Propensity-score-adjusted odds ratio for eradication
    2.89 ratio
    Semaglutide recipients
    95% CI of adjusted odds ratio for eradication
    1.24 to 6.74 ratio
    Semaglutide recipients

    Source sentences

    Summary
    When applying a propensity-score-adjusted analysis, eradication remained significantly increased among individuals who received semaglutide (OR 2.89, 95% CI 1.24-6.74, p = 0.014).
    2 context sentences
    Summary · context
    Adults with a new diagnosis of H. pylori infection who received treatment between 2014 and 2023 were identified in the Clalit Health Services database.
    Summary · context
    A 1:2 propensity-score matched dataset was used to determine the effect of GLP-1 drugs on eradication success.

Studies that did not test the peptide alone3

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In treated adults with H. pylori, pooled GLP-1 drugs including dulaglutide showed no significant eradication difference versus no exposure.

    In plain wordsIn adults treated for H. pylori, eradication did not differ significantly with pooled GLP-1 drugs including dulaglutide versus no exposure.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeH. pylori eradication
    Study

    n: not reported in source

    Comparator
    No GLP-1 drug exposure
    Outcome group
    Infection and antimicrobial activity · Infection

    Measurements

    Eradication rate
    86.6%
    Adults treated for H. pylori who received GLP-1 drugs
    Eradication rate
    83.7%
    Adults treated for H. pylori who did not receive GLP-1 drugs

    Source sentences

    Summary
    Eradication among those who did and did not receive GLP-1 drugs was 86.6% and 83.7%, respectively (p = 0.059 across subgroups).
    2 context sentences
    Summary · context
    Adults with a new diagnosis of H. pylori infection who received treatment between 2014 and 2023 were identified in the Clalit Health Services database.
    Summary · context
    A 1:2 propensity-score matched dataset was used to determine the effect of GLP-1 drugs on eradication success.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 06HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome

    In treated adults with H. pylori, pooled GLP-1 drugs including liraglutide showed no significant eradication difference versus no exposure.

    In plain wordsIn adults treated for H. pylori, eradication did not differ significantly with pooled GLP-1 drugs including liraglutide versus no exposure.

    Peptide
    Liraglutide
    Outcome
    No significant changeH. pylori eradication
    Study

    n: not reported in source

    Comparator
    No GLP-1 drug exposure
    Outcome group
    Infection and antimicrobial activity · Infection

    Measurements

    Eradication rate
    86.6%
    Adults treated for H. pylori who received GLP-1 drugs
    Eradication rate
    83.7%
    Adults treated for H. pylori who did not receive GLP-1 drugs

    Source sentences

    Summary
    Eradication among those who did and did not receive GLP-1 drugs was 86.6% and 83.7%, respectively (p = 0.059 across subgroups).
    2 context sentences
    Summary · context
    Adults with a new diagnosis of H. pylori infection who received treatment between 2014 and 2023 were identified in the Clalit Health Services database.
    Summary · context
    A 1:2 propensity-score matched dataset was used to determine the effect of GLP-1 drugs on eradication success.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 07HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In treated adults with H. pylori, pooled GLP-1 drugs including semaglutide showed no significant eradication difference versus no exposure.

    In plain wordsIn adults treated for H. pylori, eradication did not differ significantly with pooled GLP-1 drugs including semaglutide versus no exposure.

    Peptide
    Semaglutide
    Outcome
    No significant changeH. pylori eradication
    Study

    n: not reported in source

    Comparator
    No GLP-1 drug exposure
    Outcome group
    Infection and antimicrobial activity · Infection

    Measurements

    Eradication rate
    86.6%
    Adults treated for H. pylori who received GLP-1 drugs
    Eradication rate
    83.7%
    Adults treated for H. pylori who did not receive GLP-1 drugs

    Source sentences

    Summary
    Eradication among those who did and did not receive GLP-1 drugs was 86.6% and 83.7%, respectively (p = 0.059 across subgroups).
    2 context sentences
    Summary · context
    Adults with a new diagnosis of H. pylori infection who received treatment between 2014 and 2023 were identified in the Clalit Health Services database.
    Summary · context
    A 1:2 propensity-score matched dataset was used to determine the effect of GLP-1 drugs on eradication success.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Versions 2 to 3

    21 Oct 2026, 18:59 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.